DXCM - MedTech Giant DexCom Spotlight Is On G7 US Launch Analyst Forecasts 22% Revenue Gain In 2024 | Benzinga
Oppenheimer analyst Steven Lichtman reiterated the Outperform rating on DexCom, Inc. (NASDAQ: DXCM), with a reduced price target of $122 from $150.
With an underpenetrated patient population and robust pipeline, Lichtman forecasts strong sales growth over the next several years for DexCom.
For '24E, Lichtman forecasts 22% sales growth on the annualization of the G7 U.S. launch, expanded CMS T2 coverage, and OUS expansion.
DexCom reported earnings of 50 cents per share, which beat the estimate of 34 cents. It clocked revenue of $975 million, compared to the ...